Oxford BioMedica (OXB) Rating Reiterated by Peel Hunt
Oxford BioMedica (LON:OXB)‘s stock had its “buy” rating reiterated by stock analysts at Peel Hunt in a report issued on Tuesday.
Shares of LON OXB traded up GBX 9.90 ($0.13) during midday trading on Tuesday, hitting GBX 722 ($9.43). 55,861 shares of the company traded hands, compared to its average volume of 6,890,000. Oxford BioMedica has a 12-month low of GBX 4.44 ($0.06) and a 12-month high of GBX 13.19 ($0.17).
In other Oxford BioMedica news, insider Lorenzo Tallarigo acquired 291 shares of the business’s stock in a transaction on Monday, September 24th. The shares were acquired at an average price of GBX 913 ($11.93) per share, for a total transaction of £2,656.83 ($3,471.62). Insiders have purchased 1,050 shares of company stock worth $797,369 in the last quarter.
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Recommended Story: Should You Consider an Index Fund?
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.